57
Foundations of Pharmaceutical Science

Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

  • Upload
    others

  • View
    2

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Foundations of Pharmaceutical Science

Page 2: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Foundations of Pharmaceutical Science

(Voigt) (Hass, Voigt, Balaz)

(Hass, Cen)

Page 3: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Medicinal Chemistry

Discipline of chemistry focused on the influence of chemical structure on the delivery and pharmacological activity and metabolism of drug molecules

Related Disciplines:• Organic Chemistry• Biochemistry• Pharmacology• Pharmaceutics

Page 4: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Medicinal Chemistry

Organic Chemistry• Drug Structure (Functional Groups, Stereochemistry,

Physiochemical Properties)• Structure-Activity Relationships• Drug Design and Development

Biochemistry• Drug Transport• Enzymes and Enzyme Activity • Endogenous Compounds

Page 5: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Pharmacology (Pharmacodynamics)• Drug-Receptor Interactions and Signal Transduction• Dose-Response (Potency, Efficacy)• Mechanism of Action

Pharmaceutics (ADME; Pharmacokinetics)• Drug administraton and absorption• Drug distribution• Drug metabolism and excretion

Page 6: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Bioavailability• The extent (how much) and the rate (how fast) that the

active drug or drug metabolite reaches the systemic circulation/target site of action. action.

• Factors influencing bioavailability• Drug structure/physiochemical properties• Mode of administration• Formulation• Drug/food interactions• Disease state• Individual metabolic differences

Page 7: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Chemical Structure & Pharmacologic Activity

Pharmacophore

The minimum structural elements, functional groups and 3D arrangement of a compound necessary to cause a biological response

Non-essential parts of the molecule are referred to as auxophore(s)

Pharmacophore revealed through systematic structural modification and pharmacologic testing

Page 8: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

N

OH

OH

H3C

Levorphanol(morphinan)

HO

N

O OH

OH

H3C

Morphine

remove dihydrofuran

(analgesic, addictive)

(4X more potent analgesic, retains addictive properties)

N

OH

H3C

Benzomorphan

remove cyclohexene

(less potent than morphine but also less addictive)

NH3C

Meperidine(10-12% less potent than morphine but also less addictive)

O

OCH2CH3

remove cyclohexane

Page 9: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Influence of Drug Structure

Physiochemical properties of drugs refers to the influence of functional groups on:

polarityionizationsolubility

molecular shape

These factors influence pharmacokinetics and pharmacodynamics

Page 10: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Drug Polarity

Polarity of a drug refers to the extent of charge separation in a molecule.

• Factors that decrease polarity (lipophilic)– Hydrocarbon elements

• Factors that increase polarity of a drug include:(hydrophilic)– Formal charges (ionization)– Polar covalent bonds– Lone pair electrons– Hydrogen bonding

Page 11: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Drug Polarity

N

N

N

H O

OOH

N

H

N

O

S

O

OH

Apalicillin(antibacterial)

lipophilic region

hydrophilic region

Both lipophilic and hydrophilic regions are present within most drug molecules

Page 12: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Drug Polarity

N

O

OCH3

CH3

Femoxetine

δ+

δ−

δ−

δ−

δ−

Polar covalent bonds and lone pair electrons contribute to drug polarity

Page 13: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Drug Polarity

Ionizable functional groups have the potential of contributing to polarity by generating a formal charge

N

N

N

H O

OOH

N

H

N

O

S

O

OH

Apalicillin(antibacterial)

O

OR

ionizable functional group

Page 14: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Drug Polarity

Substituents can influence pKa and ionization

O

O

H

EWG

EWG = electron-withdrawing group(i.e., nitro)

δ+

O

O

EWG

δ+

EWG: Stabilizes conjugate baseincreases Ka, decreases pKa

decrease electron density around ring by resonance or inductive

effects

O

O

H

EDG

EDG = electron-donating group(i.e., halogens)

δ−

O

O

EDG

δ−

EDG: Destabilizes conjugate basedecreases Ka, increases pKa

increase electron density around ring by resonance or inductive

effects

Page 15: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Drug PolarityHydrogen bonding

H-bonds are weak interactions that occur between a H atom (bonded to an electronegative element) and the lone pair electrons of another atom within the same molecule (intramolecular) or another molecule (intermolecular).

O

O

O

O CH3

H

intramolecular H-bond

intermolecular H-bond

O

O

O

O CH3

H

O

O

O

O CH3

H

Page 16: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Polarity and Non-Covalent Bonding Interactions

• Non-covalent interactions are weak interactions between functional groups of like polarity within (intra) or between (inter) molecules

• Types of non-covalent interactions include:– H-bonds– Dipole-dipole– Ion-dipole– Hydrophobic Interactions

Page 17: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Polarity and Non-Covalent Bonding Interactions

Cl

O N

Toremifene

δ+δ+ δ−

δ−

δ−

Cl

O Nδ+δ+

δ−δ−

δ−

Dipole-Dipole

H3COOCH3

OH3C

O

OOCH3

δ+

δ−

δ−folding

Intermolecular

Intramolecular

Page 18: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Polarity and Non-Covalent Bonding Interactions

O

CH3

O

NH3C

H3C CH3 δ−

δ− δ+

O

CH3

O

NH3C

H3C CH3 δ−

δ− δ+

Ion-Dipole

O

CH3

O

N

H3CCH3

CH3

δ−

δ+

Intermolecular

Intramolecular

Page 19: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Polarity and Non-Covalent Bonding Interactions

H2N

HN

OH

O

O

H2N

HN

OH

O

O

Hydrophobic

H2NNH

O

O

OH

Intermolecular

Intramolecular

Page 20: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Polarity and Water Solubility

O

CH3

O

NH3C

H3C CH3 δ−

δ−

δ+O

H H

HO

H

HO

H

δ+

δ−

Hydrogen bonding and ion-dipole bonding contribute to water solubility

Intermolecular H-bonding between drug functional groups and water increases water solubility

Intramolecular H-bonding or ion dipole bonding within a drug does not allow solvation by water and diminishes water solubility

O

CH3

O

N

H3CCH3

CH3

δ−

δ+

Page 21: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Molecular Shape

OOH

A B C Receptor

Specific functional groups on drug bind to specific sites on receptor.Groups must be oriented properly to accommodate specific binding

Page 22: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Molecular Shape

• Spatial arrangement of functional groups influences physiochemical properties of drugs

• Isomers, molecules with the same molecular formula but different structural arrangement of atoms, have different physiochemical and pharmacologic properties

Page 23: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Isomers

Drug isomers have the same molecular formula with a different arrangement of atoms

Isomers

Constitutional Configurational

Skeletal PositionalFunctionalgroup

Conformational

Stereoisomers

Enantiomers Diastereomers

Page 24: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Stereochemistry

• Two general types of stereoisomers:

– Configurational: same structural formula except different arrangement of atoms around a chiral element in the molecule (enantiomers, diastereomers, cis/trans isomers)

– Conformational: same structural formula different spatial arrangements due to rotation around sigma bonds

Page 25: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Stereochemistry

Configurational

Diastereomers Enantiomers

Conformational

Stereoisomers

Page 26: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Geometric Isomers

OH

AH

H

C

BA

B

C

OH

AB

C

H

H

AB

C

Differences in 3D orientation of functional groups results in different receptor binding

A C A C

H H

A C

A H

H C

(cis/trans; E/Z; syn/anti)

Page 27: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Enantiomers• Non-superimposable mirror image isomers that arise due to the

chirality of an atom or of the overall molecule. Referred to as R/S, D/L or d/l (dextro/levo) isomers

• Enantiomers have identical physical properties (i.e., energy, boiling point, melting point, densities, etc.) except that they rotate the plane of polarized light in different directions.

• Enantiomeric drugs do not necessarily have the same biological activity, and often have very different biological activity.

• Many drugs are sold as racemic mixtures. Racemic mixtures are 50:50 mixtures of enantiomers. FDA requires that individual enantiomers be separated and tested for biological activity even if the drug is to be sold as a racemate.

Page 28: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Enantiomers

• d- Propoxyphene (DARVON) and l- propoxyphene (NOVRAD) are enantiomers

• The d- isomer (trade name DARVON) is a narcotic analgesic. Its l-enantiomer is NOVRAD which is an antitussive agent (cough suppressant)

O

O

O

N

O

N

(+) propoxyphene

(DARVON)

(-) levopropoxyphene

(NOVRAD)

Page 29: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Enantiomers

AB

C AB

C

D

A BC

B

A DC

Differences in 3D orientation of functional groups around chiral center results in different receptor binding and different pharmacological activity

Page 30: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Diastereomers

• Diastereomers are non-superimposable, non-mirror image stereoisomers.

• Diastereomers arise in molecules with more than one chiral center or chiral element

• Diastereomers have different physical properties and different pharmacological activity

Page 31: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Enantiomers & Diastereomers

NH

OO

N

O

OHO

Enalapril(antihypertensive)

* *

*

NH

OO

N

O

OHO

enantiomer of enalapril

NH

OO

N

O

OHO

diastereomer of enalapril

Molecules with more than one chiral center can have both enantiomers and diastereomers.

Page 32: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Conformational Isomers

• Conformers are isomers which arise due to rotation about a carbon-carbon single bond.

• Rotation around carbon-carbon single bonds may occur without any breaking of covalent bonds.

• Some conformers or conformational isomers may experience unfavorable interactions which give rise to higher energy conditions.

Page 33: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Conformational Isomers

C C

HH 3C

H H

H H

C C

HH

H H

CH 3 H

Page 34: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Conformational Isomers

X

C

ZY

A BA

B

C

B

C

ZY

X AA

B

C

Page 35: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Conformational Isomers

O

HHH H

O

CH3

N

H H

N

OO

CH3

HH

Ester-binding site

Hydrophobic bindingsite

Anionic-bindingsite

Ester-binding site

Hydrophobic bindingsiteAnionic-binding

site

Acetylcholine conformers

Page 36: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Structure Activity Relationships (SAR)

• Structurally specific drugs (majority)

– act at a specific target site such as a receptor or enzyme to produce a biological effect

– modification of structure gives rise to modification in activity (SAR)

• Structurally nonspecific drugs– no specific site of action– less dependence of activity on specific drug structure

Page 37: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Drug DiscoveryStructure Modification

O

HOH

CCH

O

CH3

CH3

O

CH3

progesterone norgestrel

HO

OH

CCH

17α-ethynyl estradiolHO

OH

H

estradiol

Endogenous Synthetically Modified

Highlighted portions of molecules illustrate auxophores

Page 38: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Structure Activity Relationships (SAR)OHO

O

OAcOH

O

AcO

O

O

OH

NH

O

paclitaxol

A

B

C

DE

F

G

H

I

J

A N-acyl group required F Change of stereochemistry or esterification does not change activity

B Phenyl or analog required G Oxetane or other small ring required for activity

C Free hydroxyl or hydrolyzable group required H Removal of acetoxy reduces activity; other acyl analogs have improved activity

D Acetoxy may be removed w/out loss of activity

I Acyloxy required; substituted benzyloxy improves activity

E Reduction of ketone improves activity slightly

J Removal of hydroxyl reduces activity slightly

Page 39: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Qualitative and Quantitative SAR

• Structural Modification of Lead Compounds(Qualitative SAR)– Homologation– Chain branching– Ring/chain transformations– Positional isomerization– Bioisosterism (“functional group equivalents”)

• Structural modification results in changes to pharmacodynamics (affinity, efficacy, potency) and pharmacokinetics (ADME)

Page 40: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Structural Modification of Lead CompoundsHomologation

• Homologation refers to progressive increases in hydrocarbon chain length(-CH2 units; methyl, ethyl, propyl, etc)

• General trend is an increase followed by a decrease in activity that correlates with lipophilicity (log P)

• Increase in activity correlates with greater bioavailability. Decrease in activity occurs when reduced water solubility interferes with transport in aqueous media or formation of micelles

1 2 3 4 5 6 7 8 9 10 11 12

Hydrocarbon chain length

activity

micelle

Page 41: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Structural Modification of Lead CompoundsHomologation

R

OH

OH

4-Alkylresorsinol antibacterial activityR = n-propyl (5%); n-butyl (22%);

n-pentyl (33%); n-hexyl (51%);n-heptyl (30%); n-octyl (0%)

Page 42: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Structural Modification of Lead CompoundsChain Branching

• Branching imposes steric changes that affect receptor binding

• Chain branching in the aminoalkylphenothiazines promethazine and promazine results in binding to different receptors

N

S

N

N

S

N

1

23

12

3

branched straight chain

promethazine promazine

ANTIPSYCHOTICANTIHISTAMINE

Page 43: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Structural Modification of Lead CompoundsRing Chain Transformations

• Ring chain transformations generally provide conformational rigidity (in the ring) and conformational flexibility (in the chain)

• Ring structures in local anesthetics enhance binding at active sites in the receptor by “holding” groups in place

N N

CH3

CH3

CH3

CH3

NH

O

N

Ring Chain

CH3

CH3

NH

O

NH3C

Chain

Lignocaine MepivacaineIsogramine

Lipophilic

DipoleAnionic

Page 44: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Structural Modification of Lead CompoundsPositional Isomerization

• Altering the position of functional groups modifies receptor binding and changes pharmacokinetics

• Replacement of the cathechol moeity of adrenergic agents with a resorcinol moeity enhances selectivity for β2-adrenergic receptors

• Resorcinol derivatives have longer duration of action since the COMT enzyme does not metabolize these compounds

HO

HO

NHR

OH

Norepinephrine R = HEpinephrine R = CH3

cathechol

COMT(catechol O-methyltransferase)

H3CO

H3CO

NHR

OH

HO NH

OH

OH Metaproterenol

resorcinol

COMT(catechol O-methyltransferase)X

H3CO NH

OH

OCH3

Page 45: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Structural Modification of Lead CompoundsBioisosterism

• Bioisosteres are substituents or functional groups with steric and electronic similarities that produce broadly similar biological properties

• Two types of bioisosteres– Classical isosteres– Non-classical isosteres

Page 46: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Structural Modification of Lead CompoundsBioisosterism

Page 47: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Structural Modification of Lead CompoundsBioisosterism

• Non-classical Isosteres– substitution of

substituents with groups not defined by classical isosteric terms but still bear steric and electronic similarities

Page 48: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Quantitative Structure Activity Relationships

• Electronic effects (Hammett equation)– assigns value (σ) to substituents to account for

electron donating/electron withdrawing character of substituents based on inductive and resonance effects

• Lipophilicity and partition coefficient (Hansch equation)– assigns value (P) to molecules to account for

lipophilic character

• Steric Effects (Taft Equation)– assigns value (E) to substituents to account for steric

effects

Page 49: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Quantitative Structure Activity RelationshipsElectronic effects (Hammett equation)

EWD = electron-withdrawing groupEDG = electron-donating group

Electronic Effects

Resonance effects-alters electron density via

delocalization of pi electrons

Inductive Effects-alters electron density based on

differences in electonegativity (EN)

EWG-atom directly bonded to parent

part of another pi system

EDG-atom directly bonded to parent

has lone pair

EWG-atom directly bonded to parent more EN

Page 50: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Quantitative Structure Activity RelationshipsElectronic effects (Hammett equation)

Both inductive and resonance effects contribute to a substituent’s ability to be an EDG or EWG.

H3CO

R R

OCH3

H3CO

R R

OCH3

para meta

H3CO

R

R

OCH3

δ−

δ+

δ+

δ−

RESONANCE INDUCTION

Page 51: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Quantitative Structure Activity RelationshipsElectronic effects (Hammett equation)

• For meta and para substituted benzoic acids, Hammett showed a linear relationship between the ED-ability/EW ability of a substituent and the Ka of the acid (ortho- skewed by steric effects and does not correlate)

log Ka

log

k

p-NO2

m-NO2m-Cl

p-Cl

p-F

m-CH3

o-NO2

o-Clo-F

p-OCH3

log kslog k0

= σρ

σ = electronic parameter (substituent) ρ = reaction constant

ks = rate of ionization for substituent k0 = rate of ionization for H

Page 52: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Quantitative Structure Activity RelationshipsElectronic effects (Hammett equation)

• The σ values are used to predict electron-donating and electron-withdrawing character of substituents in drugs

• The σmeta values follow inductive trend; σ para follow resonance trend

• Values are additive and constitutive

Substituent Abbreviation σ meta σ para

acetamido- AcNH- 0.21 -0.01

acetoxy- AcO- 0.39 0.31

acetyl- Ac- 0.38 0.50

amino- NH 2- -0.16 -0.66

bromo- Br- 0.39 0.23

tert-butyl- (CH 3)3C- -0.10 -0.20

chloro- Cl- 0.37 0.23

cyano- NC- 0.56 0.66

ethoxy- EtO- 0.10 -0.24

ethyl- Et- -0.07 -0.15

fluoro- F- 0.34 0.06

hydrogen H- 0.00 0.00

hydroxy- HO- 0.12 -0.37

methoxy- MeO- 0.12 -0.27

methyl- Me- -0.07 -0.17

nitro- NO2- 0.71 0.78

phenyl- Ph- 0.06 -0.01

trifluoromethyl F3C- 0.43 0.54

trimethylamino- (CH 3)3N +- 0.88 0.82

Page 53: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Quantitative Structure Activity RelationshipsLipophilicity and Partition Coefficient

• Partition coefficient (lipophilicity) can be correlated with biological activity

• Three models– linear– parabolic– bilinear

log

1/B

R

log P0-4 4-2 2

4

-4

-2

0

2

Page 54: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Quantitative Structure Activity RelationshipsLipophilicity and Partition Coefficient (Hansch)

• Lipophilic character of specific substituents can be determined and correlated with the partition coefficient

• The value π is used to indicate lipophilic character of specific substituents

Substituent π

H 0.00

-CH 3 0.56

-CH 2CH 3 1.02

-CH 2CH 2CH 3 1.55

-C(CH 3)3 1.53

-OCH 3 -0.02

-NH 2 -1.23

-F 0.14

-Cl 0.71

-Br 0.86

-I 1.12

-CF3 0.88

-OH -0.67

-COCH 3 -0.55

-NHCOCH 3 -0.97

-NO2 -0.8

-CN -0.57

Page 55: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Quantitative Structure Activity RelationshipsLipophilicity and Partition Coefficient (Hansch) equation)

The partition coefficient (lipophilicity) of a compound can be calculated from π values of its substituents

diethylstibestrol

OH

HO

log P = 2πCH3 + 2πCH2 + πCH=CH + 2logPPhOH

= 2(0.50) + 2(0.50) + 0.69 + 2(1.46) = 5.61

Experimental log P = 5.07

Page 56: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Quantitative Structure Activity RelationshipsSteric Effects (Taft Equation)

• Taft Equation-Es represents the steric contribution of a particular group based on rates of hydrolysis α-substituted acetates

Es = logkxCO2Me – logkmethyl acetate

H3C

O

OCH3

H+

H2O H3C

O

OH

+ HOCH3

X

O

OCH3

H+

H2O X

O

OH

+ HOCH3

k = rate constant for acid catalyzed hydrolysis

Page 57: Foundations of Pharmaceutical ScienceStructure Activity Relationships (SAR) • Structurally specific drugs (majority) – act at a specific target site such as a receptor or enzyme

Quantitative Structure Activity RelationshipsSteric Effects (Taft Equation)

N

H

N

CH3

CH3

Cl

S(+)-dexchlorpheniramine

N

H

Cl

N

CH3

CH3

R(-)-dexchlorpheniramine

The S-enantiomer is 200 times more potent than the R as 1H receptor antagonist.

How does changing the sterics affect potency?